|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11433046||AZURITY||Compositions and methods for treating epilepsy, seizures and other conditions|| |
(17 years from now)
Market Authorisation Date: 05 November, 2021
Treatment: Indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age and older; Indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; Indicated for the preventive treatment of migraine in patients 12 years and older
Click on the highlighted region to filter.